Business Description
Abionyx Pharma
ISIN : FR0012616852
Share Class Description:
LTS:0RAG: Ordinary SharesCompare
Compare
Traded in other countries / regions
ABNX.France609.Germany0RAG.UK IPO Date
2015-08-20Description
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.21 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.43 | |||||
Debt-to-EBITDA | -1.01 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.7 | |||||
Beneish M-Score | -2.72 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -11.3 | |||||
3-Year EPS without NRI Growth Rate | -13.8 | |||||
3-Year FCF Growth Rate | -57.5 | |||||
3-Year Book Growth Rate | -3.3 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 20.62 | |||||
9-Day RSI | 35.76 | |||||
14-Day RSI | 46.17 | |||||
6-1 Month Momentum % | -0.47 | |||||
12-1 Month Momentum % | 1.27 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.75 | |||||
Quick Ratio | 1.7 | |||||
Cash Ratio | 1.05 | |||||
Days Inventory | 15.94 | |||||
Days Sales Outstanding | 67.55 | |||||
Days Payable | 157.57 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.7 | |||||
Shareholder Yield % | -10.03 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 13.32 | |||||
Operating Margin % | -68.21 | |||||
Net Margin % | -75.82 | |||||
FCF Margin % | -82.5 | |||||
ROE % | -53.08 | |||||
ROA % | -23.72 | |||||
ROIC % | -28.58 | |||||
ROC (Joel Greenblatt) % | -146.77 | |||||
ROCE % | -35.29 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 7.66 | |||||
PB Ratio | 4.73 | |||||
Price-to-Tangible-Book | 15.43 | |||||
EV-to-EBIT | -10.55 | |||||
EV-to-EBITDA | -11.03 | |||||
EV-to-Revenue | 7.95 | |||||
EV-to-FCF | -9.61 | |||||
Earnings Yield (Greenblatt) % | -9.48 | |||||
FCF Yield % | -10.17 |